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Abstract
The role of lateral lymph node dissection (LLND) during total mesorectal excision (TME) for rectal cancer is still controversial.
Many reviews were published on prophylactic LLND in rectal cancer surgery, some biased by heterogeneity of overall associated
treatments. The aim of this systematic review and meta-analysis is to perform a timeline analysis of different treatments
associated to prophylactic LLND vs no-LLND during TME for rectal cancer.
Methods A literature searchwas performed in PubMed, SCOPUS andWOS for publications up to 1 September 2020.We considered
RCTs and CCTs comparing oncologic and functional outcomes of TME with or without LLND in patients with rectal cancer.
Results Thirty-four included articles and 29 studies enrolled 11,606 patients. No difference in 5-year local recurrence (in every
subgroup analysis including preoperative neoadjuvant chemoradiotherapy), 5-year distant and overall recurrence, 5-year overall
survival and 5-year disease-free survival was found between LLND group and non LLND group. The analysis of post-operative
functional outcomes reported hindered quality of life (urinary, evacuatory and sexual dysfunction) in LLND patients when
compared to non LLND.
Conclusion Our publication does not demonstrate that TME with LLND has any oncological advantage when compared to
TME alone, showing that with the advent of neoadjuvant therapy, the advantage of LLND is lost. In this review, the most
important bias is the heterogeneous characteristics of patients, cancer staging, different neoadjuvant therapy, different radiother-
apy techniques and fractionation used in different studies. Higher rate of functional post-operative complications does not support
routinely use of LLND.
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Introduction
Although commonly performed in urologic (1) and
gynaecologic (2) surgery, the role of lateral lymph node dissec-
tion (LLND) is still a very controversial topic in rectal cancer
treatment (3). This procedure, reported in Japan in the 1970s (4,
5), was standardized byMoriya at the end of the 1980s: “On the
basis of the extent of lateral node spread, two types of lateral
node dissection were performed, consisting of preservation of
internal iliac vessels (conventional) and en-bloc excision of
these vessels (extended)” (6).
Currently, total mesorectal excision (TME) remains the
gold standard for surgical treatment of mid and low rectal
cancer. In contrast, the place of LLND remains a matter of
controversy between Eastern and Western surgical guidelines
(7–12). The main conceptual difference is the fact that the
lateral pelvic lymph nodes are considered as localized disease
in Japanese clinical practice, whereas the West treats them as
systemic disease (13–15). For this reason, in Japan, prophy-
lactic LLND is always performed in patients with stage II/III
lower rectal cancer, whereas in the West, chemoradiotherapy
(CRT) is routinely performed, thus generally avoiding a more
invasive surgical approach (16).
To date, seven systematic reviews and meta-analyses have
provided the highest levels of evidence to support the role of
LLND for rectal cancer (17–23). This new systematic review
and meta-analysis aims to perform an updated analysis of the
different types of treatments associated with prophylactic
LLND vs. no-LLND (NLLND) in rectal cancer surgery.
Methods
We performed a systematic review adhering to AMSTAR 2
principles (24). A literature search was performed from two
authors (R.C., F.B.) in PubMed, SCOPUS and WOS for pub-
lications up to 1 September 2020. The protocol for this study
was registered on PROSPERO, a prospective international da-
tabase for reviews under the registration number 42020186525.
Inclusion criteria We considered RCTs (randomized control
trial) and CCTs (clinical control trials) comparing patients
with rectal cancer who underwent rectal resection and TME
with versus without LLND.
Exclusion criteria Patients having surgery without TME.
The Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) guidelines were followed
(25)(ESM6). The keywords used for PubMed database re-
searchwere: “extended lymphadenectomy,” “pelvic lymphad-
enectomy,” “lateral lymph-node dissection,” “total mesorectal
excision,” “rectal resection,” “rectal cancer,” and their combi-
nations. The search strategy performed on PubMed was the
following: “extended lymphadenectomy”[All Fields] AND
(“rectum”[MeSH Terms] OR rectum[All Fields]) “pelvic
lymphadenectomy “[All Fields] AND (rectum[MeSH
Terms] OR rectum[All Fields]) “lateral lymph-node
dissection”[All Fields] AND (rectum[MeSH Terms] OR
rectum[All Fields]).
We also manually searched the references of identified ar-
ticles and relevant reviews and searched conference proceed-
ings, theses and published abstracts on Google scholar. No
language restriction was applied.
Outcomes The primary outcomes were the incidence of local
recurrence and distant recurrence at 5 years. The secondary
outcomes were the 5-year overall and disease-free survival
and the incidence of urinary dysfunction (retention), urinary
incontinence, evacuatory dysfunction and sexual dysfunction.
The assessment of methodological quality was performed
independently by two authors (RC, CR). The risk of bias of
randomized control trials (RCTs) was assessed using methods
described in the Cochrane Handbook for Systematic Reviews
of Interventions (26) and the ROBINS-I tool (27) for obser-
vational studies. In the ROBINS-I tool, risk of bias is assessed
within specified domains, including bias due to confounding,
bias in selection of participants into the study, bias in classifi-
cation of interventions, bias due to deviations from intended
interventions bias due to missing data, bias in measurement of
outcomes, bias in selection of the reported result and overall
bias. Bias assessments were tabulated with explanation.
Disagreements were resolved via discussion between the in-
vestigators. Graphic representation of the results was pro-
duced using the Robvis online tool (28) (ESM4-5).
Statistical analysis
This meta-analysis was conducted using the Review Manager
(RevMan version 5.3.5) computer program (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
The dichotomous outcomes were pooled with a random-
effects model with the Mantel-Haenszel method to estimate
risk ratios (RRd) and their 95% confidence intervals (29).
Clinical heterogeneity was tested using τ2, Cochrane’s Q
and I2 statistics. We considered an I2 value exceeding 50%
to be indicative of heterogeneity (30).
We used a random-effect analysis model for the high clin-
ical heterogeneity and statistically significant higher chi2 val-
ue and I2 (31). In all remaining circumstances, we used the
random-effects model.
The following subgroup analyses were performed to re-
duce the heterogeneity:
& LLND vs. NLLND
& LLND vs. NLLND and adjuvant therapy
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Table 1 Included studies
Author and year
of publication










1 Tsukamoto 2020 (40) Japan RCT 2003-2010 Rectum L II/III 701 NR
2 Oki
2019 (46)




3 Nishizaki 2019 (47) Japan Retrospective
CCT























Japan RCT 2003-2010 Rectum NR 701 NR
8 Dev
2017 (51)
India RCT NR Rectum L II/III 240 NR
9 Georgiu 2017 (17) UK Retrospective
CCT
2006-2009 Rectum NR 38 PE
10 Ishihara 2017 (52) Japan Retrospective
CCT







Japan RCT 2003-2010 Rectum L II/III 701 RAR
12 Tamura 2017 (53) Japan Retrospective
CCT
2000-2015 Rectum L IV 50 NR
13 Kim 2017 (54) Korea Retrospective
CCT
NR Rectum L NR 377 RAR
APR
14 Ogura 2017 (48) Japan Retrospective
CCT





























1992-2006 Rectum L NR 69 NR
20 Kusters 2009 (57) Netherlands/ Japan Prospective
CCT




21 Kobayashi 2009 (58) Japan Retrospective
CCT
1991-1998 Rectum L I/II/III 1.272 NR
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& LLND and adjuvant therapy vs. NLLND and adjuvant
therapy
& LLND vs nCRT and NLLND
& nCRT and LLND vs nCRT and NLLND
Results
The PRISMA flow diagram for the systematic review is pre-
sented in SDC 1 (ESM1). The initial search yielded 2833
potentially relevant articles. After the removal of duplicates,
1767 studies underwent screening of titles/abstracts for rele-
vance and assessment for eligibility; 1724 further articles were
eventually excluded leaving 43 studies for analysis of the full
text. Of these, nine studies, included in the other systematic
review (17–23), were successively excluded (SDC 2)(ESM2)
(5, 32–39). The remaining 34 articles and 29 studies (11.606
patients: 5161 underwent LLND and 6445 NLLND) were
included in this systematic review and meta-analysis. One
study (Tsukamoto 2020) (40) overlapped with a previous
study (Fujita 2017) (41). In effect, the study of Tsukamoto
et al. is the result of a long-term follow-up of the Japan
Clinical Oncology Group (JCOG) 0212 (ClinicalTrials.gov
NCT00190541) published previously from Fujita et al. in
2017. The other studies included as RCT (40–44) are all
based on the same trial (JCOG0212) and therefore represent
the same group of patients. The studies of Nagawa 2001 (45)
and Watanabe 2002 (7) are both from the same single institu-
tion with overlapped years.
Characteristics of the studies
The 28 included studies were published between 1994 and
2020; patients were enrolled between 1985 and 2016














22 Shiozawa 2007 (59) Japan Retrospective
CCT
1990-2000 Rectum L NR 169 NR
23 Kim 2007 (60) Korea Retrospective
CCT






1995-2003 Rectum I/II/III/IV 109 RAR
APR
HP
25 Kyo 2006 (62) Japan Prospective
CCT
1998-2000 Rectum I/II/III/IV 37 RAR
APR
HP
26 Col 2005 (63) Turkey Retrospective
CCT
1997-2000 Rectum NR 170 RAR
APR
27 Hasdemir 2005 (64) Turkey Retrospective
CCT
NR Rectum U/M/L I/II/III 170 RAR
APR
28 Matsuoka 2005 (65) Japan Prospective
CCT
1998 - 2003 Rectum NR 57 RAR






30 Maeda 2003 (67) Japan Prospective
CCT
1988-1996 Rectum U/L NR 77 RAR
APR
31 Watanabe 2002 (7) Japan Retrospective
CCT










1963-1990 Rectum U/L NR 192 RAR
APR
Others
34 Moreira 1994 (69) Japan Retrospective
CCT
1981-1991 Rectum NR 178 NR
APR abdominoperineal resection, IR intersphincteric resection, LLND lateral lymph node dissection, Non-LLND non-lateral lymph node dissection, PE
pelvic exenteration, RAR rectal anterior resection, U upper, M Mid, L lower, ME mesorectal excision
2324 Int J Colorectal Dis (2021) 36:2321–2333
except one that also included patients with anal cancer (66).
The level of the cancer was reported in 22 studies. In 18
studies (85.7%%), the tumour was located in the lower rec-
tum. A small proportion of studies included patients with up-
per rectal cancer (14.3%) (64, 67, 68).
The clinical AJCC staging was reported in 17 studies
(50%): II/III stages (9 studies), I/II/III stages (4 studies), I/II/
III/IV stages (2 studies), III stage (1 study) and IV stage (1
study). A TME was performed in all patients, and the type of
rectal resection was reported in 24 studies (70.6%): anterior
resection (23 studies), abdominoperineal resection (20 stud-
ies), Hartmann’s procedure (10 studies) and pelvic exentera-
tion (3 studies).
Risk of bias Seven domains for the potential risk of bias of
included RCTs using methods described in the Cochrane
Handbook for Systematic Reviews of Interventions were
analysed (26). All studies were rated as unclear risk of random
Fig. 1 Forest plot, 5-year local recurrence
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sequence generation (selection bias) and five studies for allo-
cation concealment (selection bias). Blinding of participants
and personnel and incomplete outcome data were rated as
high risk in all included studies. Five studies were rated as
low risk of selection bias for selective reporting (reporting
bias) and other bias. The ROBINS-I tool was used to evaluate
the quality of the comparative studies.
Primary outcomes
Local recurrence at 5 years Seventeen studies (7, 17, 42, 45,
46, 48, 49, 52, 53, 57–61, 64, 66, 68, 69) reported local recur-
rence in 6613 patients (2.924 LLND and 3689 NLLND). The
incidence of local recurrence was not statistically different
between the overall LLND group (10.7%, 312/2.924) and
the overall NLLND group (12.1%, 448/3.689) (RR 0.89,
95% CI 0.69 to 1.14; I2 = 49%, P=0.36) (Fig. 1).
In the subgroup analysis of patients who underwent LLND
vs NLLND without (Fig. 1 (1.2.1)) or with adjuvant therapy
(Fig. 1 (1.2.4)), there was no statistical difference between
local recurrence rates in LLND (10.1%) and NLLND
(12.4%) group [respectively RR 0.73 (95% CI 0.53 to 1.01)
and RR 0.66 (95% CI 0.18 to 2.43)].
In the patients who underwent LLND vs NLLND with
neoadjuvant CRT, local recurrence rate was the same in
LLND and NLLND (RR 1.51, 95% CI 0.41–5.52) (Fig. 1
(1.2.2))
In all groups that underwent neoadjuvant CRT, there was
not a significant difference in local recurrence rate in LLND
group (RR 1.07, 95% CI 0.39–2.93) (Fig. 1 (1.2.5)).
Distant recurrence at 5 years Four studies (7, 17, 45, 46, 60),
including 888 patients (388 LLND and 500 NLLND), report-
ed the rate of distant recurrence.
There was no significant difference in distant recurrence
rate between the LLND group (28.6%, 110/388) and the
NLLND group (30%, 150/500) (RR 0.93, 95% CI 0.66 to
1.32; I2 = 39%) (Fig. 2). In the subgroup analysis, the results
did not show a statistically significant advantage for any group
of patients, despite the better results in NLLND with neoad-
juvant CRT compared with LLND alone (RR 1.42, 95% CI
0.58–3.46) (Fig. 2 (2.1.2)).
Fig. 2 Forest plot 5-year distant recurrence
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Secondary outcomes
Overall 5-year survival Ten studies (41, 45, 46, 52, 53, 55,
58–60, 64, 69), including 5132 patients (2560 LLND and
2572 NLLND), reported the rate of this outcome. The overall
survival at 5 years was not statistically different between the
LLND group (76.6%) and the NLLND group (74.6%), (RR
0.90, 95% CI 0.79 to 1.01; I2 = 17%) (Fig. 3).
Disease-free 5-year survival Six studies (41, 45–47, 59, 60, 64),
including 1922 patients (913 LLND and 1054 NLLND), re-
ported the rate of this outcome. There was no statistical differ-
ence in terms of disease-free survival at 5 years when compar-
ing the LLND group (67.9%) to the NLLND group (65%), (RR
0.87, 95% CI 0.75 to 1.01; I2 = 24%) (Fig. 4).
Urinary retention Seven studies (43, 45, 46, 50, 62, 63, 67),
including 1718 patients (665 LLND and 1053 NLLND), re-
ported urinary dysfunction. The incidence of urinary retention
was significantly higher in the LLND patients (37%) if com-
pared to the NLLND group (24.4%) (RR 1.88, 95% CI 1.11 to
3.19; I2 = 68%) (Fig. 5).
Urinary incontinence Four studies (62, 63, 65, 67), includ-
ing 341 patients (119 LLND and 222 NLLND), reported
urinary incontinence. The incidence of urinary inconti-
nence was similar between the LLND group (23.5%)
and the NLLND group (27.4%) (RR 1.35, 95% CI 0.94
to 1.92; I2 = 0%) (Fig. 6).
Sexual dysfunction Four studies (44, 45, 62, 67), including
140 patients (27 LLND and 57 NLLND), reported sexual
dysfunction. The incidence of sexual dysfunction was similar
between the LLND group (61.7%) and the NLLND group
(47%) (RR 1.87, 95% CI 0.91 to 3.84; I2 = 65%) (Fig. 7).
Evacuatory dysfunction Two studies (45, 65), including 84
patients (27 LLND and 57 NLLND), reported evacuatory
Fig. 3 Forest plot overall survival at 5 years
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dysfunction. The incidence of evacuatory dysfunction was sim-
ilar between the LLND group (62.9%) and the NLLND group
(43.9%) (RR 1.57, 95% CI 1.00 to 2.47; I2 = 15%) (SDC
3)(ESM3).
Discussion
Rectal cancer represents the third leading cause of death
worldwide with a steadily increasing incidence (70, 71). The
concept of TME, introduced by Heald, has revolutionized the
treatment by reducing the local recurrence rates from up to
40% to 4–8% (15, 71). TME does not include the removal
of the lateral pelvic lymph nodes but only those found within
the mesorectal fascia and along the course of the mesenteric
vessels. The efficacy of the excision of the pelvic lateral
lymph nodes is still a controversial topic (72, 73).
The lymphatic drainage of the rectum, especially for the
most distal/lower rectum, through the submucosal plexus,
drains in three trunks: the upper branch, which flows into the
lymphatic channels of the lower mesenteric vein; the middle
branch, draining to the lymph nodes surrounding the internal,
external and common iliac vessels; the lower branch draining
to the inguinal lymph nodes (15) (Table 2; Fig. 8). These lateral
regional lymphatic areas outside of the mesorectum are classi-
fied into six regions near the following arteries: the internal
Fig. 4 Forest plot disease-free survival at 5 years
Fig. 5 Forest plot urinary dysfunction (retention)
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pudendal (outside of the pelvic plexus), the internal iliac (prox-
imal to the superior vesical artery), the common iliac, the ex-
ternal iliac, the obturator and the presacral regions. Among
these regions, the internal iliac artery and obturator regions
have the highest rate of nodal involvement (22-61%) and are
called the ‘vulnerable field’ (13, 14).
The different approaches to the LLND between the East and
West stems from the concept that pelvic lateral lymph nodes
are considered regional according to Japanese authors and stag-
ing systems. The Western world, with the latest AJCC guide-
lines (AJCC 8th edition), confirms pelvic lateral lymph node
stations as remote stations. This is mainly debated in the case of
stage II and III low rectal cancer. The involvement of lymph
node stations in the iliac and obturator regions varies from 10.6
to 25.5% (15) stage II and III rectal cancer below the peritoneal
reflection. More specifically, pelvic extra-regional lymph node
involvement is reported in 5.4% of T1 cases, 8.2% for T2,
16.5% for T3 and 37.2% for T4 (58). For this reason,
Japanese surgeons suggest performing TME with bilateral pel-
vic lymphadenectomy without neoadjuvant treatment, as they
expect that the risk of intrapelvic recurrence decreases by 50%,
and 5-year survival improves by 8 to 9% (7, 8).
On the contrary, surgeons of the Western world generally
treat rectal cancer with a classical TME and often considering
neoadjuvant CRT(74), preserving LLND for patients with clin-
ically suspected lateral pelvic lymph node metastasis (9–11).
The comparison between LLND versus CRT for lateral pel-
vic lymph nodes mainly concerns the rate of local pelvic recur-
rence. The only RCT comparing these two surgical techniques
is JCOGO212 (41), which compared TME vs. TME and lateral
pelvic lymphadenectomy in patients who had no lateral pelvic
lymphadenopathy before surgery. The rate of local recurrence
decreased from 12.6% in cases of TME alone to 7.4% when
TME was associated with lateral lymphadenectomy. A limita-
tion of this study was the choice of not performing preoperative
CRT before TME, even when it would have been indicated
according to Western guidelines (12, 74). Long-term follow-
up of JCOGO212 confirms the non-inferiority of TME alone
compared to TME with pelvic lymphadenectomy in patients
without clinically identifiable pelvic lymph node involvement.
The study concludes that pelvic lateral lymphadenectomy
should only be performed in patients with radiological evidence
of lymph node involvement.
Other studies (54) confirm that the risk of pelvic recurrence
rises to 19.5% in patients with lateral pelvic lymph nodes of a
size more than 7 mm after neoadjuvant therapy. On the other
hand, there is little evidence on the true efficacy of bilateral
pelvic lymphadenectomy for low rectum carcinomas without
clinical evidence of bilateral pelvic lymphadenopathy (41).
Although TME alone should not be considered inferior to
TME with lateral lymphadenectomy, surgery extended to lat-
eral pelvic lymph nodes reduces the risk of pelvic recurrence,
especially in radiologically positive cases.
The main point of the discussion remains the risk of lateral
pelvic lymph node metastases even after neoadjuvant CRT.
The literature (72) reports a high percentage (up to 30–40%)
of pelvic lymph node involvement even after neoadjuvant
CRT.
The results from the present analysis confirm that the more
radical and invasive surgical approach does not appear to be
the safest and optimal way to treat these patients. The com-
parison between LLND and NLLND groups showed no
Fig. 6 Forest plot urinary incontinence
Fig. 7 Forest plot sexual dysfunction
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difference in the rate of local recurrence and distant metasta-
ses. The central role in the prevention of local recurrences
seems to be the use of neoadjuvant CRT, as the only group
with statistically improved results was the non-LLND with
neoadjuvant CRT when compared to LLND only.
Regarding overall survival, the cumulative analysis also re-
vealed a lack of any advantage of LLND, but the subgroup
analysis did show improved overall survival in the group with
LLND plus neoadjuvant CRT.
The main concern for the more invasive surgical approach
of LLND is additional complications. It is recognized that
higher occurrence of urinary, defecatory and sexual dysfunc-
tions is found after LLND (3, 75), despite the introduction of
nerve-sparing techniques. In the present analysis, the inci-
dence of urinary retention and incontinence and sexual dys-
functions was directly compared in patients with and without
LLND. The only statistically significant difference was the
higher incidence of urinary retention in patients undergoing
LLND. Another possible confounding factor is the fact that
the comparison in most cases was carried out on patients with-
out CRT, which is a procedure also burdened with similar and
potentially additional, functional complications. More
targeted studies are needed to assess the safety and quality
of life following LLND surgery.
An important limitation of the present analysis is the pos-
sible bias introduced by the high heterogeneity of the clinical
and oncological status of the included patients. Furthermore,
our analysis could be expanded and completed by examining
other data, such as the number of harvested lymph nodes,
additional lymph node metastases detected in the LLND
group and differences in functional outcomes between mini-
mally invasive surgeries versus open resections.
Conclusion
Our results suggest that TME with LLND does not offer an
oncological advantage over TME without LLND. The advan-
tage of LLND in the pre-neoadjuvant CRT era is lost after the
implementation of neoadjuvant CRT. The addition of adju-
vant CRT to LLND appears to contribute towards better sur-
vival and diminishes the rate of local recurrences. Whilst in-
curring in heterogeneity of data analysing currently available
literature, the evidence would suggest that there is no place for
routine LLND in the management of rectal cancer.
These findings reiterate the importance of careful selection
of patients for LLND through an improved definition of path-
ological lymph nodes. Improved imaging techniques to accu-
rately define a reliable cut-off size and describe radiological
abnormalities that accurately predict involvement of pelvic
lymph nodes are needed. Further studies, preferably prospec-
tive, that focus on survival and its association with surgical
technique are needed to establish an evidence-based cut-off,
which would aid in identifying precise indications for LLND.
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Table 2 Lymphatic drainage of the rectum
Lymphatic drainage Lymph node group Tributary Veins
Upper branch Rectosigmoid nodes Lower mesenteric vein












Fig. 8 Lymphatic drainage of the rectum
2330 Int J Colorectal Dis (2021) 36:2321–2333
References
1. Silberstein JL, Vickers AJ, Power NE, Parra RO, Coleman JA,
Pinochet R, Touijer KA, Scardino PT, Eastham JA, Laudone VP
(2012) Pelvic lymph node dissection for patients with elevated risk
of lymph node invasion during radical prostatectomy: Comparison
of open, laparoscopic and robot-assisted procedures. J Endourol
26(6):748–753
2. Wisner KPA, Ahmad S, Holloway RW (2017) Indications and
techniques for robotic pelvic and para-aortic lymphadenectomy
with sentinel lymph node mapping in gynecologic oncology.
Bailliere Tindall Ltd:83–93
3. Koch M, Kienle P, Antolovic D, Büchler MW, Weitz J (2005) Is
the lateral lymph node compartment relevant? Recent Results
Cancer Res:40–45
4. Hojo K, Koyama Y, Moriya Y (1982) Lymphatic spread and its
prognostic value in patients with rectal cancer. Am J Surg 144(3):
350–354
5. Koyama Y, Moriya Y, Hojo K (1984) Effects of Extended
Systematic Lymphadenectomy for Adenocarcinoma of the
Rectum—Significant Improvement of Survival Rate and
Decrease of Local Recurrence—. Jpn J Clin Oncol 14(4):623–632
6. Moriya Y, Hojo K, Sawada T, Koyama Y (1989) Significance of
lateral node dissection for advanced rectal carcinoma at or below
the peritoneal reflection. Dis Colon Rectum 32(4):307–315
7. Watanabe T, Tsurita G, Muto T, Sawada T, Sunouchi K, Higuchi
Y, Komuro Y, Kanazawa T, Iijima T, Miyaki M, Nagawa H (2002)
Extended lymphadenectomy and preoperative radiotherapy for
lower rectal cancers. Surgery. 132(1):27–33
8. Sugihara K, Kobayashi H, Kato T,Mori T, Mochizuki H, Kameoka
S, Shirouzu K, Muto T (2006) Indication and benefit of pelvic
sidewall dissection for rectal cancer. Dis Colon Rectum 49(11):
1663–1672
9. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J,
Miedema B, Ota D, Sargent D, National Cancer Institute Expert
Panel (2001) Guidelines 2000 for colon and rectal cancer surgery.
J Natl Cancer Inst 93(8):583–596
10. Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie
WD et al (2013) Practice parameters for the management of rectal
cancer (revised). Dis Colon Rectum 56(5):535–550
11. Xynos E, Tekkis P, Gouvas N, Vini L, Chrysou E, Tzardi M,
Vassiliou V, Boukovinas I, Agalianos C, Androulakis N,
Athanasiadis A, Christodoulou C, Dervenis C, Emmanouilidis C,
Georgiou P, Katopodi O, Kountourakis P, Makatsoris T,
Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis
G, Pilpilidis I, Sgouros J, Triantopoulou C, Xynogalos S,
Karachaliou N, Ziras N, Zoras O, Souglakos J, [the Executive
Team on behalf of the Hellenic Society of Medical Oncologists
(HeSMO)] (2016) Clinical practice guidelines for the surgical treat-
ment of rectal cancer: a consensus statement of the Hellenic Society
of Medical Oncologists (HeSMO). Ann Gastroenterol 29(2):103–
126
12. You YN, HardimanKM, Bafford A, Poylin V, Francone TD, Davis
K, et al. The American Society of Colon and Rectal Surgeons
Clinical Practice Guidelines for the Management of Rectal
Cancer. Ovid Technologies (Wolters Kluwer Health); 2020. p.
1191-222
13. Canessa CE, Miegge LM, Bado J, Silveri C, Labandera D (2004)
Anatomic study of lateral pelvic lymph nodes: implications in the
treatment of rectal cancer. Dis Colon Rectum 47(3):297–303
14. Atef Y, Koedam TW, van Oostendorp SE, Bonjer HJ, Wijsmuller
AR, Tuynman JB (2019) Lateral Pelvic Lymph Node Metastases in
Rectal Cancer: A Systematic Review. World J Surg 43(12):3198–
3206
15. Christou N, Meyer J, Toso C, Ris F, Buchs NC (2019) Lateral
lymph node dissection for low rectal cancer: Is it necessary?
World J Gastroenterol 25(31):4294–4299
16. Otero de Pablos J, Mayol J (2020) Controversies in the
Management of Lateral Pelvic Lymph Nodes in Patients With
Advanced Rectal Cancer: East or West? Frontiers in Surgery
6(January):1–8
17. Georgiou PA, Mohammed Ali S, Brown G, Rasheed S, Tekkis PP
(2017) Extended lymphadenectomy for locally advanced and recur-
rent rectal cancer. Int J Color Dis 32(3):333–340
18. Cheng H, Deng Z,Wang ZJ, ZhangW, Su JT (2011) Lateral lymph
node dissection with radical surgery versus single radical surgery
for rectal cancer: a meta-analysis. Asian Pac J Cancer Prev 12(10):
2517–2521
19. Ma P, Yuan Y, Yan P, Chen G,Ma S, Niu X, et al. The efficacy and
safety of lateral lymph node dissection for patients with rectal can-
cer: A systematic review and meta-analysis. Asian Journal of
Surgery. 2020(xxxx)
20. Hajibandeh S, Hajibandeh S, Matthews J, Palmer L, MawA (2020)
Meta-analysis of survival and functional outcomes after total
mesorectal excision with or without lateral pelvic lymph node dis-
section in rectal cancer surgery. Surgery. 168(3):486–496
21. Longchamp G, Meyer J, Christou N, Popeskou S, Roos E, Toso C,
Buchs NC, Ris F (2020) Total mesorectal excision with andwithout
lateral lymph node dissection: a systematic review of the literature.
Int J Color Dis 35(7):1183–1192
22. Xiang Gao, Cun Wang, Yong-Yang Yu et al. Lateral lymph node
dissection reduces local recurrence of locally advanced lower rectal
cancer in the absence of preoperative neoadjuvant chemoradiother-
apy: A systematic review and meta-analysis, 21 September 2020,
PREPRINT (Version 2) available at Research Square [https://doi.
org/10.21203/rs.3.rs-42723/v2]
23. Law BZY, Yusuf Z, Ng YE, Aly EH (2020) Does adding lateral
pelvic lymph node dissection to neoadjuvant chemotherapy im-
prove outcomes in low rectal cancer? Int J Color Dis 35(8):1387–
1395
24. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J et al.
AMSTAR 2: A critical appraisal tool for systematic reviews that
include randomised or non-randomised studies of healthcare inter-
ventions, or both. BMJ (Online). 2017;358
25. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred
reporting items for systematic reviews and meta-analyses: the
PRISMA statement. J Clin Epidemiol 62(10):1006–1012
26. JPT Higgins, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,
Welch VA (editors) Cochrane Handbook for Systematic Reviews
of Interventions version 6.1 (updated September 2020). Cochrane,
2020. Available from www.training.cochrane.org/handbook
27. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND,
Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk
of bias in non-randomised studies of interventions. Bmj. 355:i4919
28. McGuinness LA, Higgins JPT Risk-of-bias VISualization (robvis):
An R package and Shiny web app for visualizing risk-of-bias as-
sessments. Research Synthesis Methods. 2020;n/a(n/a)
29. Mantel N, Haenszel W (1959) Statistical Aspects of the Analysis of
Data From Retrospective Studies of Disease. JNCI: Journal of the
National Cancer Institute 22(4):719–748
30. Rücker G, Schwarzer G, Carpenter JR, Schumacher M (2008)
Undue reliance on I2 in assessing heterogeneity may mislead.
BMC Med Res Methodol 8(1):79
31. Kontopantelis E, Springate DA, Reeves D (2013) A re-analysis of
the Cochrane Library data: the dangers of unobserved heterogeneity
in meta-analyses. PLoS One 8(7):e69930
32. Otowa Y, Yamashita K, Kanemitsu K, Sumi Y, Yamamoto M,
Kanaji S, Imanishi T, Nakamura T, Suzuki S, Tanaka K, Kakeji
Y (2015) Treating patients with advanced rectal cancer and lateral
2331Int J Colorectal Dis (2021) 36:2321–2333
pelvic lymph nodes with preoperative chemoradiotherapy based on
pretreatment imaging. Onco Targets Ther 8:3169–3173
33. Dong XS, Xu HT, Yu ZW, Liu M, Cu BB, Zhao P, Wang XS
(2003) Effect of extended radical resection for rectal cancer.
World J Gastroenterol 9(5):970–973
34. Shirouzu K, Ogata Y, Araki Y, Sasatomi T, Nozoe Y, NakagawaM
et al (2001) Total Mesorectal Excision, Lateral Lymphadenectomy
and Autonomic Nerve Preservation for Lower Rectal Cancer:
Significance in the Long-term Follow-up Study. Kurume Med J
48(4):307–319
35. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van
Houwelingen HC, van de Velde CJH (1999) Improved survival
and local control after total mesorectal excision or D3 lymphade-
nectomy in the treatment of primary rectal cancer: an international
analysis of 1411 patients. Eur J Surg Oncol 25(4):368–374
36. Michelassi F, Block GE (1992) Morbidity and mortality of wide
pelvic lymphadenectomy for rectal adenocarcinoma. Dis Colon
Rectum 35(12):1143–1147
37. Hojo K, Sawada T, Moriya Y (1989) An analysis of survival and
voiding, sexual function after wide iliopelvic lymphadenectomy in
patients with carcinoma of the rectum, compared with conventional
lymphadenectomy. Dis Colon Rectum 32(2):128–133
38. Michelassi F, Block GE, Vannucci L, Montag A, Chappell R
(1988) A 5- to 21-year follow-up and analysis of 250 patients with
rectal adenocarcinoma. Ann Surg 208(3):379–389
39. Enker WE, Pilipshen SJ, Heilweil ML, Stearns MW Jr, Janov AJ,
Hertz RE et al (1986) En bloc pelvic lymphadenectomy and sphinc-
ter preservation in the surgical management of rectal cancer. Ann
Surg 203(4):426–433
40. Tsukamoto S, Fujita S, Ota M, Mizusawa J, Shida D, Kanemitsu Y,
Ito M, Shiomi A, Komori K, Ohue M, Akazai Y, Shiozawa M,
Yamaguchi T, Bando H, Tsuchida A, Okamura S, Akagi Y,
Takiguchi N, Saida Y, Akasu T, Moriya Y (2020) Long-term fol-
low-up of the randomized trial of mesorectal excision with or with-
out lateral lymph node dissection in rectal cancer (JCOG0212). Br J
Surg 107(5):586–594
41. Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K,
OhueM, OtaM, Akazai Y, ShiozawaM, Yamaguchi T, Bandou H,
Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y,
Nakamura K, Fukuda H, Akasu T, Moriya Y, Colorectal Cancer
Study Group of Japan Clinical Oncology Group (2017) Mesorectal
Excision with or Without Lateral Lymph Node Dissection for
Clinical Stage II/III Lower Rectal Cancer (JCOG0212). Ann Surg
266(2):201–207
42. Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y,
OhueM, Fujii S, ShiozawaM, Yamaguchi T,Moriya Y, Colorectal
Cancer Study Group of Japan Clinical Oncology Group (2012)
Postoperative morbidity and mortality after mesorectal excision
with and without lateral lymph node dissection for clinical stage II
or stage III lower rectal cancer (JCOG0212): Results from a
multicentre, randomised controlled, non-inferiority trial. The
Lancet Oncology 13(6):616–621
43. Ito M, Kobayashi A, Fujita S, Mizusawa J, Kanemitsu Y, Kinugasa
Y, Komori K, OhueM, OtaM, Akazai Y, ShiozawaM, Yamaguchi
T, Akasu T, Moriya Y, Colorectal Cancer Study Group of Japan
Clinical Oncology Group (2018) Urinary dysfunction after rectal
cancer surgery: Results from a randomized trial comparing
mesorectal excision with and without lateral lymph node dissection
for clinical stage II or III lower rectal cancer (Japan Clinical
Oncology Group Study, JCOG0212). Eur J Surg Oncol 44(4):
463–468
44. Saito S, Fujita S, Mizusawa J, Kanemitsu Y, Saito N, Kinugasa Y,
Akazai Y, OtaM, OhueM, Komori K, ShiozawaM, Yamaguchi T,
Akasu T, Moriya Y (2016) Male sexual dysfunction after rectal
cancer surgery: Results of a randomized trial comparing mesorectal
excision with and without lateral lymph node dissection for patients
with lower rectal cancer: Japan Clinical Oncology Group Study
JCOG0212. Eur J Surg Oncol 42(12):1851–1858
45. Nagawa H, Muto T, Sunouchi K, Higuchi Y, Tsurita G, Watanabe
T, Sawada T (2001) Randomized, controlled trial of lateral node
dissection vs. nerve-preserving resection in patients with rectal can-
cer after preoperative radiotherapy. Dis Colon Rectum 44(9):1274–
1280
46. Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K,
Kusumoto T, Munemoto Y, Nakanishi R, Nakashima Y, Saeki H,
Maehara Y (2019) Effect of lateral lymph node dissection for mid
and low rectal cancer: An ad-hoc analysis of the ACTS-RC
(JFMC35-C1) randomized clinical trial. Surgery. 165(3):586–592
47. Nishizaki D, Hida K, Sumii A, Sakai Y, Konishi T, Akagi T et al
(2019) Neoadjuvant chemoradiotherapy with/without lateral lymph
node dissection for low rectal cancer: Which patients can benefit?
Ann Oncol 30(October):v205–v20v
48. Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H,
Toda S, Lee IK, Lee HX, Uehara K, Lee P, Putter H, van de Velde
CJH, Beets GL, Rutten HJT, Kusters M, on behalf of the Lateral
Node Study Consortium (2019) Neoadjuvant (chemo)radiotherapy
with total mesorectal excision only is not sufficient to prevent lateral
local recurrence in enlarged nodes: Results of the multicenter lateral
node study of patients with low ct3/4 rectal cancer. J Clin Oncol
37(1):33–43
49. Matsuda T, Sumi Y, Yamashita K, Hasegawa H, Yamamoto M,
Matsuda Y, Kanaji S, Oshikiri T, Nakamura T, Suzuki S, Kakeji Y
(2018) Outcomes and prognostic factors of selective lateral pelvic
lymph node dissection with preoperative chemoradiotherapy for
locally advanced rectal cancer. Int J Color Dis 33(4):367–374
50. Park BK, Lee SJ, Hur BY, Kim MJ, Chan Park S, Chang HJ, Kim
DY, Oh JH (2018) Feasibility of selective lateral node dissection
based on magnetic resonance imaging in rectal cancer after preop-
erative chemoradiotherapy. J Surg Res 232:227–233
51. Dev K, Veerenderkumar KV, Krishnamurthy S (2018) Incidence
and Predictive Model for Lateral Pelvic Lymph Node Metastasis in
Lower Rectal Cancer. Indian J Surg Oncol 9(2):150–156
52. Ishihara S, Kawai K, Tanaka T, Kiyomatsu T, Hata K, Nozawa H,
Morikawa T, Watanabe T (2017) Oncological outcomes of lateral
pelvic lymph node metastasis in rectal cancer treated with preoper-
ative chemoradiotherapy. Dis Colon Rectum 60(5):469–476
53. Tamura H, Shimada Y, Kameyama H, Yagi R, Tajima Y, Okamura
T, Nakano M, Nakano M, Nagahashi M, Sakata J, Kobayashi T,
Kosugi SI, Nogami H, Maruyama S, Takii Y, Wakai T (2017)
Prophylactic lateral pelvic lymph node dissection in stage IV low
rectal cancer. World Journal of Clinical Oncology 8(5):412–419
54. Kim HJ, Choi GS, Park JS, Park SY, Cho SH, Lee SJ, Kang BW,
Kim JG (2017) Optimal treatment strategies for clinically suspi-
cious lateral pelvic lymph node metastasis in rectal cancer.
Oncotarget. 8(59):100724–100733
55. Ozawa H, Kotake K, Hosaka M, Hirata A, Sugihara K (2016)
Impact of Lateral Pelvic Lymph Node Dissection on the Survival
of Patients with T3 and T4 LowRectal Cancer. World J Surg 40(6):
1492–1499
56. Akiyoshi T, Toda S, Tominaga T, Oba K, Tomizawa K, Hanaoka
Y, Nagasaki T, Konishi T, Matoba S, Fukunaga Y, Ueno M,
Kuroyanagi H (2019) Prognostic impact of residual lateral lymph
node metastasis after neoadjuvant (chemo)radiotherapy in patients
with advanced low rectal cancer. BJS open 3(6):822–829
57. Kusters M, Beets GL, Van De Velde CJH, Beets-Tan RGH,
Marijnen CAM, Rutten HJT et al (2009) A comparison between
the treatment of low rectal cancer in japan and the netherlands,
focusing on the patterns of local recurrence. Ann Surg 249(2):
229–235
58. Kobayashi H, Mochizuki H, Kato T, Mori T, Kameoka S, Shirouzu
K, Sugihara K (2009) Outcomes of surgery alone for lower rectal
2332 Int J Colorectal Dis (2021) 36:2321–2333
cancer with and without pelvic sidewall dissection. Dis Colon
Rectum 52(4):567–576
59. Shiozawa M, Akaike M, Yamada R, Godai T, Yamamoto N, Saito
H, Sugimasa Y, Takemiya S, Rino Y, Imada T (2007) Lateral
l ymph nod e d i s s e c t i o n f o r l owe r r e c t a l c a n c e r .
Hepatogastroenterology. 54(76):1066–1070
60. Kim JC, Takahashi K, Yu CS, Kim HC, Kim TW, Ryu MH, Kim
JH, Mori T (2007) Comparative outcome between chemoradiother-
apy and lateral pelvic lymph node dissection following total
mesorectal excision in rectal cancer. Ann Surg 246(5):754–762
61. Yano H, Saito Y, Takeshita E, Miyake O, Ishizuka N (2007)
Prediction of lateral pelvic node involvement in low rectal cancer
by conventional computed tomography. Br J Surg 94(8):1014–
1019
62. Kyo K, Sameshima S, Takahashi M, Furugori T, Sawada T (2006)
Impact of autonomic nerve preservation and lateral node dissection
onmale urogenital function after total mesorectal excision for lower
rectal cancer. World J Surg 30(6):1014–1019
63. Çöl C, Hasdemir O, Yalcin E, Guzel H, Tunc G, Bilgen K,
Kucukpinar T (2005) The assessment of urinary function following
extended lymph node dissection for colorectal cancer. Eur J Surg
Oncol 31(3):237–241
64. Hasdemir O, Cöl C, Yalçin E, Tunç G, Bilgen K, Kuçukpinar T
(2005) Local recurrence and survival rates after extended system-
atic lymph-node dissection for surgical treatment of rectal cancer.
Hepatogastroenterology. 52(62):455–459
65. Matsuoka H, Masaki T, Sugiyama M, Atomi Y (2005) Impact of
lateral pelvic lymph node dissection on evacuatory and urinary
functions following low anterior resection for advanced rectal car-
cinoma. Langenbeck's Arch Surg 390(6):517–522
66. Fujita S, Yamamoto S, Akasu T, Moriya Y (2003) Lateral pelvic
lymph node dissection for advanced lower rectal cancer. Br J Surg
90(12):1580–1585
67. Maeda K, Maruta M, Utsumi T, Sato H, Toyama K, Matsuoka H
(2003) Bladder and male sexual functions after autonomic nerve-
sparing TME with or without lateral node dissection for rectal can-
cer. Techniques in Coloproctology 7(1):29–33
68. Suzuki K, Muto T, Sawada T (1995) Prevention of local recurrence
by extended lymphadenectomy for rectal cancer. Surg Today 25(9):
795–801
69. Moreira LF, Hizuta A, Iwagaki H, TanakaN, Orita K (1994) Lateral
lymph node dissection for rectal carcinoma below the peritoneal
reflection. Br J Surg 81(2):293–296
70. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A
(2018) Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin 68(6):394–424
71. Albandar MH, Cho MS, Bae SU, Kim NK (2016) Surgical man-
agement of extra-regional lymph node metastasis in colorectal can-
cer. Expert Rev Anticancer Ther 16(5):503–513
72. Oh H-K, Kang S-B, Lee S-M, Lee SY, Ihn MH, Kim D-W, Park
JH, Kim YH, Lee KH, Kim JS, Kim JW, Kim JH, Chang TY, Park
SC, Sohn DK, Oh JH, Park JW, Ryoo SB, Jeong SY, Park KJ
(2014) Neoadjuvant chemoradiotherapy affects the indications for
lateral pelvic node dissection in mid/low rectal cancer with clinical-
ly suspected lateral node involvement: a multicenter retrospective
cohort study. Ann Surg Oncol 21(7):2280–2287
73. Williamson JS, Quyn AJ, Sagar PM (2020) Rectal cancer lateral
pelvic sidewall lymph nodes: a review of controversies and man-
agement. Br J Surg 107:1562–1569
74. Colorectal cancer - NICE guideline [NG151] - Published date: 29
January 2020
75. Chan DKH, Tan K-K, Akiyoshi T (2019) Diagnostic and manage-
ment strategies for lateral pelvic lymph nodes in low rectal cancer—
a review of the evidence. Journal of Gastrointestinal Oncology
10(6):1200–1206
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
2333Int J Colorectal Dis (2021) 36:2321–2333
